{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:55:38Z","timestamp":1771008938190,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Program on Hepatitis from the Japan Agency for Medical Research and Development, AMED","award":["16fk0210301h0003"],"award-info":[{"award-number":["16fk0210301h0003"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182710","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T17:57:40Z","timestamp":1502387860000},"page":"e0182710","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":42,"title":["The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy"],"prefix":"10.1371","volume":"12","author":[{"given":"Yuko","family":"Nagaoki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Daijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Teraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hatooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reona","family":"Morio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Morio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiiku","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"issue":"4 PT 1","key":"ref1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.1840120409","article-title":"Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus","volume":"12","author":"K Kiyosawa","year":"1990","journal-title":"Hepatology"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/hep.510280632","article-title":"Prognosis of chronic hepatitis C: results of a large, prospective cohort study","volume":"28","author":"C Niederau","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.1840180109","article-title":"A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis","volume":"18","author":"K Ikeda","year":"1993","journal-title":"Hepatology"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"G Fattovich","year":"1997","journal-title":"Gastroenterology"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.510270529","article-title":"Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C","volume":"27","author":"A Kasahara","year":"1998","journal-title":"Hepatology"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","article-title":"Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis","volume":"29","author":"K Ikeda","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1089-3261(05)70244-0","article-title":"Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma","volume":"3","author":"T Poynard","year":"1999","journal-title":"Clin Liver Dis"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan","volume":"131","author":"H Yoshida","year":"1999","journal-title":"Ann Intern Med"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.2003.030353","article-title":"Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C","volume":"53","author":"H Yoshida","year":"2004","journal-title":"Gut"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/jgh.13236","article-title":"Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study","volume":"31","author":"Y Nagaoki","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"H Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00535-016-1255-4","article-title":"Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C","volume":"52","author":"R Morio","year":"2017","journal-title":"J Gastroenterol"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","article-title":"Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis","volume":"62","author":"H Kumada","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.27705","article-title":"Randomized trial of interferon- and ribavirin-free ombitasvir\/paritaprevir\/ritonavir in treatment-experienced hepatitis C virus-infected patients","volume":"61","author":"K Chayama","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hepr.12621","article-title":"Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients","volume":"46","author":"E Miyaki","year":"2016","journal-title":"Hepatol Res"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jmv.24663","article-title":"Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection","volume":"89","author":"M Kobayashi","year":"2017","journal-title":"J Med Virol"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000450551","article-title":"Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals","volume":"91","author":"N Akuta","year":"2016","journal-title":"Oncology"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.13821","article-title":"Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon","volume":"45","author":"S Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Y Tanaka","year":"2009","journal-title":"Nat Genet"},{"issue":"Pt 6","key":"ref22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1099\/vir.0.060103-0","article-title":"IFNL4\/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population","volume":"95","author":"H Ochi","year":"2014","journal-title":"J Gen Virol"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ng.876","article-title":"Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers","volume":"43","author":"D Miki","year":"2011","journal-title":"Nat Genet"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","article-title":"ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy\u2014a genome-wide study of Japanese HCV virus patients","volume":"139","author":"H Ochi","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1572-0241.2007.01590.x","article-title":"Ten common statistical errors and how to avoid them","volume":"103","author":"AR Zinsmeister","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0016-5085(86)90436-1","article-title":"Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans","volume":"91","author":"P Layer","year":"1986","journal-title":"Gastroenterology"},{"issue":"8 Pt 2","key":"ref27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores","volume":"127","author":"DB Rubin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"19","key":"ref28","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"RB D\u2019Agostino Jr","year":"1998","journal-title":"Stat Med"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"F Conti","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"M Reig","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection","volume":"64","author":"HB El-Serag","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000074472","article-title":"Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients","volume":"65","author":"K Ikeda","year":"2003","journal-title":"Oncology"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1478-3231.2006.01406.x","article-title":"Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1,124 patients","volume":"27","author":"S Kobayashi","year":"2007","journal-title":"Liver Int"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","article-title":"\u03b1-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C","volume":"58","author":"Y Asahina","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2017.01.041","article-title":"Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection","volume":"152","author":"K Matsuura","year":"2017","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T04:08:16Z","timestamp":1540354096000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182710"}},"subtitle":[],"editor":[{"given":"Ming-Lung","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182710","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]}}}